Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy

Optimal timing of initiating antiretroviral therapy has been a controversial topic in HIV research. Two highly publicized studies applied different analytical approaches, a dynamic marginal structural model and a multiple imputation method, to different observational databases and came up with different conclusions. Discrepancies between the two studies' results could be due to differences between patient populations, fundamental differences between statistical methods, or differences between implementation details. For example, the two studies adjusted for different covariates, compared different thresholds, and had different criteria for qualifying measurements. If both analytical approaches were applied to the same cohort holding technical details constant, would their results be similar? In this study, we applied both statistical approaches using observational data from 12,708 HIV-infected persons throughout the USA. We held technical details constant between the two methods and then repeated analyses varying technical details to understand what impact they had on findings. We also present results applying both approaches to simulated data. Results were similar, although not identical, when technical details were held constant between the two statistical methods. Confidence intervals for the dynamic marginal structural model tended to be wider than those from the imputation approach, although this may have been due in part to additional external data used in the imputation analysis. We also consider differences in the estimands, required data, and assumptions of the two statistical methods. Our study provides insights into assessing optimal dynamic treatment regimes in the context of starting antiretroviral therapy and in more general settings. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[2]  J. Robins,et al.  Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.

[3]  R B D'Agostino,et al.  Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. , 1990, Statistics in medicine.

[4]  Richard D Moore,et al.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. , 2008, International journal of epidemiology.

[5]  S. Cole,et al.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies , 2004, Statistics in medicine.

[6]  R. Pomerantz Initiating antiretroviral therapy during HIV infection: confusion and clarity. , 2001, JAMA.

[7]  Sally S Bebawy,et al.  Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy , 2010, Epidemiology.

[8]  Roger A. Sugden,et al.  Multiple Imputation for Nonresponse in Surveys , 1988 .

[9]  S. Vermund,et al.  Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. , 2013, American journal of epidemiology.

[10]  J. Robins,et al.  G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis carinii Pneumonia on the Survival of AIDS Patients , 1992, Epidemiology.

[11]  S. Buchbinder,et al.  Early versus deferred antiretroviral therapy for HIV. , 2009, The New England journal of medicine.

[12]  J. Robins,et al.  Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.

[13]  James M. Robins,et al.  The International Journal of Biostatistics CAUSAL INFERENCE When to Start Treatment ? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data , 2011 .

[14]  J. Lundgren,et al.  When to start antiretroviral therapy: the need for an evidence base during early HIV infection , 2013, BMC Medicine.

[15]  S. Murphy,et al.  Optimal dynamic treatment regimes , 2003 .

[16]  J. Robins,et al.  Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. , 2009, International journal of epidemiology.

[17]  J. Carpenter,et al.  Optimal CD4 Count for Initiating HIV Treatment , 2014, Epidemiology.

[18]  F. Dominici,et al.  Reproducible epidemiologic research. , 2006, American journal of epidemiology.

[19]  N P Jewell,et al.  Statistical models for prevalent cohort data. , 1993, Biometrics.

[20]  Marie Davidian,et al.  Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. , 2013, Biometrika.

[21]  H. Bang,et al.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. , 2010, The New England journal of medicine.

[22]  M. Saag,et al.  When to start antiretroviral therapy: as soon as possible , 2013, BMC Medicine.

[23]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[24]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[25]  Stephen R Cole,et al.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.

[26]  James M Robins,et al.  When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.

[27]  Stephen R Cole,et al.  The consistency statement in causal inference: a definition or an assumption? , 2009, Epidemiology.

[28]  M. J. van der Laan,et al.  Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules , 2007, The international journal of biostatistics.

[29]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[30]  M. J. van der Laan Targeted Maximum Likelihood Based Causal Inference: Part I , 2010, The international journal of biostatistics.

[31]  James M. Robins,et al.  Comparative Effectiveness of Dynamic Treatment Regimes: An Application of the Parametric G-Formula , 2011, Statistics in biosciences.

[32]  Anastasios A. Tsiatis,et al.  Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2012, Statistical science : a review journal of the Institute of Mathematical Statistics.

[33]  S. Cole,et al.  Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. , 2011, Archives of internal medicine.

[34]  Sally S Bebawy,et al.  Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. , 2009, The Journal of infectious diseases.

[35]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[36]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[37]  Mark J van der Laan,et al.  Targeted Maximum Likelihood Based Causal Inference: Part II , 2010, The international journal of biostatistics.

[38]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[39]  A. Phillips,et al.  Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study , 2013, Clinical trials.